Public Employees Retirement System of Ohio Purchases New Stake in Novo Nordisk A/S $NVO

Public Employees Retirement System of Ohio acquired a new position in Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 321,841 shares of the company’s stock, valued at approximately $15,429,000.

A number of other institutional investors have also recently bought and sold shares of NVO. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $25,000. Transamerica Financial Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 201.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock valued at $31,000 after buying an additional 403 shares during the period. Johnson Financial Group Inc. grew its holdings in shares of Novo Nordisk A/S by 128.0% during the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock valued at $38,000 after acquiring an additional 384 shares in the last quarter. Scarborough Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at $26,000. Finally, Kingdom Financial Group LLC. acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth $41,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on NVO. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Trading Down 0.0%

Novo Nordisk A/S stock opened at $45.59 on Monday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The company’s fifty day moving average price is $48.03 and its two-hundred day moving average price is $43.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The company has a market capitalization of $203.56 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 4.08 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. On average, analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a dividend of $0.5786 per share. The ex-dividend date of this dividend was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is presently 20.05%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.